ST 2825

ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity[1][2].

Product Specifications

CAS Number

[894787-30-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MyD88

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ST-2825.html

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N([C@H]1C(N)=O)[C@@](SCC1)([H])C2)[C@]2(CCC3)N3C(CC4=CC=C(C=C4)NC(COC(C(Cl)=C5)=CC=C5Cl)=O)=O

Molecular Formula

C27H28Cl2N4O5S

Molecular Weight

591.51

Precautions

H302, H315, H319, H335

References & Citations

[1]Loiarro M, et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol. 2007 Oct;82 (4) :801-10.|[2]Fantò N, et al. Design, Synthesis, and In Vitro Activity of Peptidomimetic Inhibitors of Myeloid Differentiation Factor 88. J Med Chem. 2008 Mar 13;51 (5) :1189-202.|[3]Van Tassell BW, et al. Pharmacologic Inhibition of Myeloid Differentiation Factor 88 (MyD88) Prevents Left Ventricular Dilation and Hypertrophy After Experimental Acute Myocardial Infarction in the Mouse. J Cardiovasc Pharmacol. 2010 Apr;55 (4) :385-90.|[4]Zhang HS, et al. Inhibition of myeloid differentiation factor 88 (MyD88) by ST2825 provides neuroprotection after experimental traumatic brain injury in mice. Brain Res. 2016 Jul 15;1643:130-9.|[5]Wang N, et al. Myeloid differentiation factor 88 is up-regulated in epileptic brain and contributes to experimental seizures in rats. Exp Neurol. 2017 Sep;295:23-35.|[6]Brad Griesenauer, et al. ST2/MYD88 signaling is a therapeutic target alleviating murine acute graft-versus-host disease sparing T regulatory cell function. Indiana University. May 2018.